4 RESULTS
COMMENT The use of a baseline tau threshold was an innovative feature of the donanemab trial, and this decision led to the discovery that baseline tau likely influences both treatment-related amyloid clearance and cognitive benefit, with the highest-tau individua
COMMENT The donanemab Phase 3 results are an exciting development for the Alzheimer's research community and for patients. These findings, alongside the aducanumab and especially the lecanemab results, should increase confidence in anti-amyloid therapy as a
COMMENT Determining the best test to assess a clinically relevant benefit, and determining what counts as meaningful change, are difficult issues to agree on. An obvious consideration here is that cognitive test scores—global, functional, and specific domains—are
COMMENT Our group has been working on longitudinal amyloid PET measurements recently, and there are a number of methodological challenges. Measuring longitudinal amyloid PET is new territory, and there is not yet a clear answer about the best way to do it. The fi
